Sanofi Xyzal OTC Antihistamine Claims Lose Second Challenge In Six Months
Executive Summary
Sanofi will modify claims in social media ads that its Xyzal Allergy 24HR antihistamine is 'twice as fast' as Bayer's s Claritin after the US National Advertising Division found the statement is not supported by head-to-head testing. NAD also recommended the firm discontinue the claim the product provides “relief that starts at hour 1 instead of hour 2.”
You may also be interested in...
Xyzal Claim To Match Zyrtec Efficacy At Half Dosage Dissolves In NAD Review
Claims that Sanofi's Xyzal 24 HR OTC product contains the same effectiveness as competitor Zyrtec but with half the medication fail a US
Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.
Sanofi’s Allegra Claims Clear NAD Review In Merck’s Second Challenge
The National Advertising Division upholds Sanofi’s claims its Allegra antihistamine is “proven effective even at 8x high pollen levels.”